Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02101554 · ClinicalTrials.gov registry record · Phase 4
Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain
A Phase 4 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT02101554 is a Phase 4 study that was terminated before completion, run by Pfizer. The registered enrollment target is 19 participants.
The verdict
NCT02101554, a Phase 4 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of morphine sulfate with a sequestered naltrexone core in children 7-17 with moderate-severe pain.
Interventions
- DRUG Ages 7-11
- DRUG ages 12-17
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2015-04-24 |
| Est. Completion | 2019-06-26 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02101554
The ClinicalTrials.gov registry entry for NCT02101554 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ages 7-11 is the first listed.
NCT02101554 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02101554 about?
NCT02101554 is a clinical study titled "Safety and Pharmacokinetic Study of EMBEDA in Children Ages 7-17 With Pain". Safety and pharmacokinetics of an abuse-deterrent, extended-release formulation of morphine sulfate with a sequestered naltrexone core in children 7-17 with moderate-severe pain.
What is the current status of trial NCT02101554?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2015-04-24. Estimated completion is 2019-06-26.
What interventions are being tested in trial NCT02101554?
The interventions under investigation include: Ages 7-11 (DRUG), ages 12-17 (DRUG).
Who is sponsoring clinical trial NCT02101554?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.